Diabetes prevalence is rising, with projections of 643 million cases by 2026 and healthcare costs exceeding $1045 billion. Nonpharmacological strategies, like Virta Health's program, demonstrate ...

Updates to NICE type 2 diabetes treatment recommendations and how nurses in primary care can implement the changes safely and ...

The study authors focused on 4 pharmacologic classes: glucocorticoids, antiretroviral therapies, newer atypical antipsychotics, and immune checkpoint inhibitors. Clinicians should be aware of the ...

Prediabetes affects 634.8 million adults globally, i.e., approximately 12% of the adult population (IDF, 2025), with 30.4% ...

In a recent study published in the journal Pharmacological Research, researchers investigated the synergistic efficacy of two glycemic control drugs – dapagliflozin and semaglutide. They carried out ...

Chronic low-grade inflammation is recognized as a component associated with insulin resistance and the progression of type 2 diabetes (T2D). In parallel, ...

Epidemiologically, T1D affects 21 to 42 million individuals worldwide, with incidence varying geographically. In the United States, approximately 1.24 million individuals are currently living with T1D ...

Learning more about diabetes care — and how to go about it — can help you create a streamlined diabetes management plan and make necessary lifestyle changes. Diabetes is a chronic medical condition ...

Smoking among people living with type 2 diabetes (T2D) is a major driver of cardiovascular morbidity and premature mortality, ...

Please provide your email address to receive an email when new articles are posted on . A new position statement focuses on making patient experiences a key component of diabetes care. The statement ...